Rockefeller Capital Management L.P. Arcutis Biotherapeutics, Inc. Transaction History
Rockefeller Capital Management L.P.
- $42.4 Billion
- Q2 2025
A detailed history of Rockefeller Capital Management L.P. transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Rockefeller Capital Management L.P. holds 21,094 shares of ARQT stock, worth $422,934. This represents 0.0% of its overall portfolio holdings.
Number of Shares
21,094
Previous 21,094
-0.0%
Holding current value
$422,934
Previous $295,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding ARQT
# of Institutions
240Shares Held
131MCall Options Held
407KPut Options Held
216K-
Suvretta Capital Management, LLC New York, NY11.5MShares$231 Million5.56% of portfolio
-
Jennison Associates LLC11.1MShares$223 Million0.09% of portfolio
-
Rubric Capital Management LP New York, NY10.7MShares$216 Million3.47% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA9.87MShares$198 Million7.3% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$173 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $1.21B
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...